Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807268 | 0.93 | GLP1R (0.46) | GLP1RTSHRALBFAAH | |
| SCHEMBL14685801 | 0.93 | GLP1R (0.48) | GLP1RTSHRALBFAAH | |
| SCHEMBL12743611 | 0.93 | GLP1R (0.46) | GLP1RTSHRALBFAAH | |
| SCHEMBL8115663 | 0.90 | GLP1R (0.51) | GLP1RTSHRALB | |
| SCHEMBL16257635 | 0.89 | GLP1R (0.47) | GLP1REPHX2ALDH1A1TSHRNAMPT | |
| SCHEMBL13539399 | 0.87 | GLP1R (0.46) | GLP1RTSHRALB | |
| SCHEMBL14685781 | 0.86 | GLP1R (0.54) | GLP1REPHX2ALDH1A1TSHRNAMPT | |
| SCHEMBL29330971 | 0.86 | GLP1R (0.51) | GLP1REPHX2ALDH1A1TSHRNAMPT | |
| SCHEMBL20144618 | 0.86 | NAMPT (0.40) | GLP1RALDH1A1TSHRNAMPTALB | |
| SCHEMBL14550361 | 0.85 | GLP1R (0.56) | GLP1REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GIPR, IAPP | GLP1R 1/4885EPHX2 4133/4885ALDH1A1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.